Insider Selling Adverum Biotechnologies, Inc. COO Sells 13,360 Shares of Stock
ADVM Stock | USD 5.93 0.04 0.68% |
About 62% of all Adverum Biotechnologies' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Adverum Biotechnologies suggests that some traders are interested. Adverum Biotechnologies' investing sentiment overview a quick insight into current market opportunities from investing in Adverum Biotechnologies. Many technical investors use Adverum Biotechnologies stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Adverum |
Adverum Biotechnologies, Inc. COO Peter Soparkar sold 13,360 shares of the stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of 0.78, for a total value of 10,420.80. Following the completion of the transaction, the chief operating officer now directly owns 265,891 shares in
Read at thelincolnianonline.com
Adverum Biotechnologies Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Adverum Biotechnologies can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Adverum Biotechnologies Fundamental Analysis
We analyze Adverum Biotechnologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adverum Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adverum Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Adverum Biotechnologies is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Adverum Biotechnologies Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adverum Biotechnologies stock to make a market-neutral strategy. Peer analysis of Adverum Biotechnologies could also be used in its relative valuation, which is a method of valuing Adverum Biotechnologies by comparing valuation metrics with similar companies.
Peers
Adverum Biotechnologies Related Equities
ABSI | Absci Corp | 8.96 | ||||
ACRV | Acrivon Therapeutics, | 8.02 | ||||
ANTX | AN2 Therapeutics | 2.65 | ||||
QURE | Uniqure NV | 2.29 | ||||
RZLT | Rezolute | 0.20 | ||||
MREO | Mereo BioPharma | 0.26 | ||||
KZR | Kezar Life | 0.72 | ||||
SLDB | Solid Biosciences | 0.79 | ||||
RYTM | Rhythm Pharmaceuticals | 1.02 | ||||
RCKT | Rocket Pharmaceuticals | 1.04 | ||||
AVTE | Aerovate Therapeutics | 1.14 | ||||
MGTX | MeiraGTx Holdings | 1.76 | ||||
STOK | Stoke Therapeutics | 2.11 | ||||
AFMD | Affimed NV | 2.59 | ||||
PASG | Passage Bio | 4.29 | ||||
GLMD | Galmed Pharmaceuticals | 5.57 | ||||
KOD | Kodiak Sciences | 10.60 | ||||
ADAG | Adagene | 16.21 |
Check out Adverum Biotechnologies Hype Analysis, Adverum Biotechnologies Correlation and Adverum Biotechnologies Performance. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share 0.059 | Quarterly Revenue Growth (0.70) | Return On Assets (0.30) | Return On Equity (0.76) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.